SpyGlass Pharma, Inc.

We are excited to share completion of enrollment in our Phase I/II trial of our drug delivery platform in patients with #glaucoma or ocular hypertension. This marks an important milestone in our effort to bring our technology to the patients who need it. Learn more:? https://lnkd.in/g5Sn98pK #SpyGlass Pharma

That wraps up another great #AAO2024! We enjoyed learning from and connecting with the best and brightest in the ophthalmology community and look forward to sharing future updates!?

New: We’re presenting 18-month follow-up data from a first-in-human study of our intraocular drug delivery platform in patients with #glaucoma or ocular hypertension during routine #Cataract surgery at Eyecelerator. Learn more: https://bit.ly/3UetR9V. #AAO2024

We are thrilled to announce the arrival of our first-ever class of interns!?????? Please join us in welcoming: Andrew, Grayson, Jose, and Rupin! These talented individuals are diving right into high-impact process optimization and method development projects with our R&D Process Development Team. They are applying the theories and concepts they've learned in their coursework on mechanical design, heat transfer, and fluid dynamics to practical, real-world applications that will drive innovation at SpyGlass. A special thank you to Craig Cable and Ashley Lara (pictured) for their exceptional efforts in facilitating and supporting our internship program. We look forward to the contributions and fresh perspectives that Andrew, Grayson, Jose, and Rupin?will bring to our team!

We continue to innovate at the intersection of #cataract surgery and #glaucoma treatment. Our vision is to provide patients with an innovative new treatment option designed to deliver multiple years of IOP-lowering therapy at the time of routine #cataract surgery. Learn More: https://lnkd.in/gZRZ77zA #CataractAwarenessMonth

?? Are you ready to make a difference in eye care? ?? At SpyGlass Pharma, Inc. we're on a mission to develop life-changing treatment options for patients suffering from ophthalmic diseases. Together we work toward our singular focus: Long-term drug delivery—that lasts. We are currently seeking passionate individuals to fill the following roles: ? Associate Director, Analytical R&D: (https://lnkd.in/dfW5k8Q2) ? ? Associate Director, Pharmaceutical Development: (https://lnkd.in/dRE8a7YA) ? Project Manager, CMC: (https://lnkd.in/diMk-k8H) ? Director, Quality Assurance: (https://lnkd.in/diz8hd9s) ? Director, Regulatory Affairs: (https://lnkd.in/dpuhBu4D) ? Office Manager: (https://lnkd.in/dUQKhwFw) ? Scientist, Pharmaceutical Development: (https://lnkd.in/dSKTgWAi) If you're looking for a challenging yet rewarding career in a dynamic and innovative environment, SpyGlass Pharma is the place for you. Join us in shaping the future of ophthalmic care, apply now!

We enjoyed attending American Society of Cataract and Refractive Surgery (ASCRS) and the opportunity to present the promising data of our innovative drug delivery platform. Hear from our Chief Medical Officer, Dr. Margot Goodkin, on the promising impact of the technology on the #glaucoma community. #ASCRS2024

Attending the American Society of Cataract and Refractive Surgery (ASCRS) annual meeting? Check out the attendee tote bags for solar eclipse glasses to safely view the eclipse on April 8 from the team at SpyGlass Pharma. Snap a selfie wearing your glasses and share with us using #ASCRS2024 and #SpyglassPharma. #Eclipse #SolarEclipse

We are proud to announce our compelling 1-year follow-up data in a first-in-human study of our intraocular drug delivery platform implanted during routine #cataract surgery in eyes with #glaucoma. https://lnkd.in/gTi2XT9A

We are excited to welcome Margot G. and Bilal Khan to our team at SpyGlass Pharma! Their experience and expertise in #ophthalmology will help drive our singular focus forward: long-term drug delivery – that lasts. Read more: https://bit.ly/3Na2I4o